STK3/STK4抗体;STK3/STK4 Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-5: PC3 cells, hela cells, human bladder carcinoma tissue, A172 cells, hepG2 cells, Primary antibody: P11626(STK3/STK4 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human Lymphoma tissue using P11626(STK3/STK4 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11626(STK3/STK4 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

The STK3 (Serine/Threonine Kinase 3) and STK4 (Serine/Threonine Kinase 4) proteins, also known as MST2 and MST1. respectively, are core components of the Hippo signaling pathway, a conserved regulator of tissue homeostasis, organ size, and apoptosis. These kinases function as tumor suppressors by phosphorylating downstream effectors like LATS1/2. which in turn inhibit YAP/TAZ transcriptional co-activators to control cell proliferation and survival. Dysregulation of STK3/STK4 is implicated in cancer, immune disorders, and neurodegenerative diseases.

Antibodies targeting STK3/STK4 are critical tools for studying Hippo pathway dynamics. They enable detection of protein expression levels, subcellular localization (e.g., cytoplasmic vs. nuclear), and activation status through phosphorylation-specific epitopes (e.g., Thr180/Thr183 in STK3/STK4). Such antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers also utilize them to investigate kinase interactions, pathway crosstalk (e.g., with Wnt or TGF-β signaling), and therapeutic responses in disease models. Due to high sequence homology between STK3 and STK4. some antibodies may cross-react, necessitating careful validation via knockout controls. Recent studies explore STK3/STK4 inhibition as a strategy to enhance tissue regeneration or counteract YAP/TAZ-driven malignancies, further driving demand for specific, high-affinity antibodies in both basic and translational research.